Pharmaceutical Executive, Feb 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT
Pharmaceutical Executive, Feb 1, 2011
Features
China: Business as UNusual
By Jon Zifferblatt
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
The Building Block of Drug Discovery
By Jill Wechsler
With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Skipping the Needle: Pharm Exec's Brand of the Year
By Jennifer Ringler
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
Columns
Tracking the US Market: A Statistical Self-Portrait
By William Looney
What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
Accelerated Evolution
By Scott Moldenhauer
Adapting training techniques is necessary to thrive in the fact-changing dynamic of a physician's office
Growing Stronger After the Storm
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
Are You Trained to Compete and Win?
By Stan Bernard, MD
With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace
Challenges, Changes, Commitments
By Jill Wechsler
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Honing Reforms from Clinical Development
Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
Worth a Pound of Cure
In an era of information overload, continuous monitoring, solutions can prevent your pharma business from losing money—and save a few lives along the way

ADVERTISEMENT

Click here